F117 - Shedding Light on Controversies in Phototherapy
Sunday, February 18; 3:30 PM - 5:30 PM
Following this course, the attendee should be able to:
- Recognize the benefits, risks, and limitations of different phototherapy modalities for various dermatologic diseases.
- Formulate and prescribe a treatment regimen for practice-based and home phototherapy.
This session goes beyond the basic how-to, examining controversial areas surrounding ultraviolet phototherapy treatment, including: 1) managing treatment of vitiligo, 2) understanding economic barriers to phototherapy, 3) prescribing home phototherapy, 4) assessing and managing photoallergy, 5) new guidelines in the treatment of cutaneous T-cell lymphoma, and 6) discussion of skin cancer risks. Practical tips for the practitioner will be emphasized.
- Buzney, Elizabeth A., MD: no financial relationships exist with commercial interests.
- Carter, Joi B., MD: Soligenix, Inc – I(Fees);
- Hamzavi, Iltefat H., MD: AbbVie – A(NC); Bayer – I(Grants/Research Funding); Clinuvel – I(Fees); Eli Lilly and Company – I(Grants/Research Funding); Estee Lauder – I(Fees); Ferndale Laboratories, Inc. – I(Fees); Galderma Laboratories, L.P. – I(Fees); Global Vitiligo Foundation – B(NC); Hidradenitis Suppurativa Foundation – B(NC); Incyte Corporation – I(Grants/Research Funding); Janssen Biotech – I(Grants/Research Funding); Lenicura – I(EQ); Pfizer Inc. – I(Fees);
- Richard, Elisabeth G., MD: UpToDate, Inc – Independent Contractor(H);
Sunday, February 18
Dr. Richard / Clinical pearls and practical matters in phototherapy
Dr. Hamzavi / Vitiligo: Do not treat it like psoriasis
Dr. Carter / Phototherapy for early stage mycosis fungoides
Dr. Buzney / Yes, you can treat this with phototherapy